Physician profile
Corey Gallus
NPI 1457333502
$4,562.58
in general payments reported to CMS, 2019-2025
38 companies · $389 in 2025
The $389 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $672 · 2020: $632 · 2021: $645 · 2022: $936 · 2023: $797 · 2024: $492 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,652 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,652.40 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $982.32 | 2021-2025 | |
| Novo Nordisk INC | $507.80 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $488.61 | 2019-2023 | Breztri, Farxiga |
| Astellas Pharma US INC | $353.72 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $280.28 | 2019-2025 | Trelegy Ellipta, Bexsero |
| Amgen INC. | $227.16 | 2019-2024 | Repatha, Otezla |
| Abbott Laboratories | $215.59 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $203.30 | 2019-2021 | |
| Pfizer INC. | $179.21 | 2020-2025 | |
| Allergan, INC. | $175.43 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $157.18 | 2019-2022 | |
| Boston Scientific Corporation | $128.23 | 2022 | |
| Novartis Pharmaceuticals Corporation | $58.96 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.17 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.49 | 2021-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $42.23 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.39 | 2023-2024 | |
| Amarin Pharma, INC. | $36.73 | 2019-2020 | |
| Eisai INC. | $34.95 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $27.27 | 2020-2025 | Zoryve |
| Supernus Pharmaceuticals, INC. | $27.16 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $25.02 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Biohaven Pharmaceuticals, INC. | $24.96 | 2020-2021 | |
| Biogen, INC. | $23.01 | 2021 | |
| Horizon Therapeutics Plc | $22.94 | 2019 | |
| Arbor Pharmaceuticals, INC. | $18.51 | 2021 | |
| Antares Pharma, INC. | $18.38 | 2025 | Xyosted |
| Alexion Pharmaceuticals, INC. | $18.00 | 2021 | |
| Merck Sharp & Dohme LLC | $16.16 | 2021 | |
| Sanofi Pasteur INC. | $15.10 | 2019 | |
| Esperion Therapeutics, INC. | $15.06 | 2021 | |
| Philips North America LLC | $14.60 | 2023 | |
| Dexcom, INC. | $14.05 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $13.79 | 2022 | |
| Therapeuticsmd, INC. | $12.80 | 2021 | |
| Medtronic USA, INC. | $12.04 | 2019 | |
| Hologic Sales and Service, LLC | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Gallus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.